Endocrine therapy resistance: current status, possible mechanisms and overcoming strategies.
Endocrine therapy resistance: current status, possible mechanisms and overcoming strategies.
复制标题
内分泌治疗抵抗：现状、可能的机制和克服策略。
DOI：
10.2174/1871520611313030009
复制
发表时间：
2013
影响因子：
2.8
通讯作者：
W. Fan
中科院分区：
文献类型：
--
作者：
Jinjia Chang;W. Fan
内分泌治疗发展迅速，已成为激素敏感性乳腺癌最有效、最明确的辅助治疗形式。乳腺癌的辅助内分泌治疗可以在手术或放疗之后进行，也可以在化疗之前或之后进行。目前常用的辅助内分泌治疗药物可分为三类：选择性雌激素受体调节剂（SERMs）、芳香化酶抑制剂（AIs）和选择性雌激素受体下调调节剂（SERDs）。不幸的是，肿瘤细胞可能对内分泌治疗产生耐药性，这成为限制乳腺癌治疗成功的主要障碍。雌激素受体与生长因子之间复杂的基因组和非基因组串扰被认为是导致内分泌抵抗的重要因素。然而，对内分泌治疗的耐药性的进展被认为是一个渐进的、循序渐进的过程，其潜在的机制尚不清楚。在这篇综述中，我们将总结内分泌抵抗可能的生物学和分子机制，以及一些克服这一问题的新策略。
Endocrine therapy has developed rapidly and become most effective and clearly target form of adjuvant therapy for hormone sensitive breast cancer. Adjuvant endocrine therapy for breast cancer can be given after surgery or radiotherapy, and also prior, or subsequent to chemotherapy. Current commonly used drugs for adjuvant endocrine therapy can be divided into following three classes: selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and selective estrogen receptor down-regulators (SERDs). Unfortunately, tumor cells may develop resistance to endocrine therapy, which become a major obstacle limiting the success of breast cancer treatment. The complicated crosstalk, both genomic and nongenomic, between estrogen receptor and growth factors was considered to be a crucial factor contributing to endocrine resistance. However, the progression of resistance to endocrine therapy supposes to be a progressive, step-wise procedure and the underlying mechanism remains unclear. In this review, we would summarize the possible biology and molecular mechanisms that underlie endocrine resistance, and also some novel strategies to overcoming this issue.